DE LA BIODIVERSIDAD A LA FARMACOLOGÍA | DIÁLOGO DE SABERES

Conferencistas

Prof. Wim Vanden Berghe obtained his PhD at the University of Ghent in 1999 in the Faculty of Science Biochemistry-Biotechnology. After postdoctoral research at various research institutions (University of Montpellier, Stellenbosch and Oxford), Wim Vanden Berghe was appointed professor of Epigenetics in 2009 in the lab for Protein chemistry, proteomics and epigenetic signaling (PPES) at the University of Antwerp and UGent. With his current research, he is looking for new epigenetic ways to prevent or inhibit diseases with the help of nutrition or bioactive substances isolated from plants that inhibit aging-related inflammatory processes in cancer, atherosclerosis obesity, diabetes or neurodegeneration.

Website:

https://www.uantwerpen.be/en/staff/wim-vandenberghe/

https://www.uantwerpen.be/en/research-groups/proteinchemistry-proteomics-epigenet/projects-and-publications/molecular-actions/

Doctor in Medicine, Specialist in Anaesthesiology and Pain Medicine Professor on Pain Clinic and Rheumatology National Service of “10 de Octubre” Hospital, Medical University of Havana, Cuba.

Senior Researcher in Neuropharmacology Lab. Institute of Sea Sciences (ICIMAR)

Bárbara Beatriz Garrido Suárez is a medical doctor, Ph. D. in Medic Sciences, specialist in Anaesthesiology and Pain Medicine, Professor from Pain Clinic and Rheumatology National Service of 10 de Octubre Hospital, University of Havana, Cuba. Currently she investigates the analgesic activity of marine-derived compounds in Pharmacology Department in Cuban Institute of Sea Sciences (ICIMAR). She received a post-doctoral training in Anesthesia Research Unit and Alan Edwards Centre for Research of Pain of McGill University as well as in Department of Pharmacology, Faculty of Medicine of Ribeirão Preto, University of São Paulo. She worked in the Center of Pharmaceutical Research and Development (CIDEM) were created the research line: Pain, potential candidate analgesics and obtained the rank of Titular Researcher. Dr. Garrido is a regular member of the International Association Study of Pain (IASP) and the secretary of its Cuban chapter. She introduced animal models and experimental methodology for the study of pain in Cuba, its clinical and research interests are aimed at understanding the peripheral and central mechanisms of neuropathic pain and evidence-based management of chronic neuropathic pain states. She has written more of 26 original research papers and reviews, 4 books chapters and is author and co-author of patents, reviewer for scientific journals, serves on the editorial board of JPPRes and received National Annual Awards of Health 2009, National Awards of Cuban Academy Sciences 2015 and National Awards of Health 2018.

Center for Research and Biological Evaluations,

Institute of Pharmacy and Food,

University of Havana, Cuba

Email: Javier.marin@ifal.uh.cu / aleph.neuro@gmail.coma

He has more than 10 years of experience in preclinical neuropharmacology. He earned all his academic degrees with honors: PhD. in Health Sciences (Biomedicine, 2015), MSc. in Neurosciences (2011), BSc. in Biochemistry (2005). He has completed 35 postgraduate courses, participated in 45 scientific events (81 presentations, 9 poster awards, president of scientific committee in 2), with 20 scientific papers (12 indexed in Web of Science; 6 as 1st author; h-index: 8; times cited: 261), 24 published abstracts, and co-author of 1 patent granted in Europe, North America and Asia countries. He was awarded with 6 international research fellowships (Brazil, Canada, Germany) and 4 international travel grants. Distinguished with more than 30 scientific recognitions, among them the Annual Awards (national level) of the Cuban Academy of Sciences (2011, 2012, 2017), the Cuban Ministry of Public Health (2010, 2011, 2012, 2013, 2018), and Awards of the Cuban Society of Pharmacology (2011-2013, 2013-2016) and the Latin-American Association of Pharmacology (2013). Supervisor of MSc. and BSc. thesis, lecturer in Cell Biology, Neurobiology and Pharmacology, and member of doctorate examining boards.

Biochemistry Degree, 1995. Faculty of Biology University of Havana.

PhD in Pharmaceutical Sciences, 1999.

Current member of the National Government Board of the Cuban Society of Pharmacology. Head of Public and international relations

Member of Admission Committee at the International Union of Basic and Clinical Pharmacology (IUPHAR)IUPHAR

Senior Research, Cuban National Drug Regulatory Authority (CECMED)

Email: didelis@cedmed.cu / diede.remirez@infomed.sld.cu

Dr. D. Remirez  Figueredo received her B.A. degree (1995, Biochemistry) from Faculty of Biology, Havana University, Cuba, and both her MSc (1995, Biomedicine) and PhD (1999 Pharmaceutical Sciences) degree from National Center for Scientific Research in Havana, and most of the results were done in the Department of Toxicology at the Free University in Amsterdam. Postdoctoral training in Molecular Toxicology and pharmacology was completed at the Faculty of Pharmacy in Toronto, Canada.

She has been referee of scientific journals related with herbal medicines. Other previous academic appointments include lecturer in different international meeting. She has been the recipient of National Award of Pharmacology twice from the Cuban Pharmacology Society. She worked as Expert for the evaluation of preclinical platform in South Africa. (CSIR). She is the WHO focal point for herbal medicines in Cuba. She is the focal point to the WHO network for regulatory cooperation of herbal medicines (IRCH). She is one of the member of International Union of Pharmacology membership committee.

She is currently the Vice president of Cuban Pharmacology Society. At present she works in the Cuba Regulatory Agency as senior researcher, she is in charge of the evaluation for authorization of clinical trials, and the evaluation of safety and efficacy of herbal medicines for registering.

Dr. Remirez research is described in over 50 published research reports.

DrC. Idania Rodeiro Guerra (PhD)

Degree in Biochemistry, University of Havana (1990).

PhD in Pharmaceutical Sciences, University of Havana (2000).

Current position: Director of Research. Institute of Marine Sciences, CITMA, Havana, Cuba.

Senior Researcher at Pharmacology Department,

Current member of the National Government Board of the Cuban Society of Pharmacology

Email: idania.rodeiro@infomed.sld.cu / idania.rodeiro@gmail.com

She studied Biochemistry in Faculty of Biology at University of Havana.

PhD in Pharmaceutical Sciences. National Center for Scientific Research.

Senior Researcher and  Full Professor at Medical University of Havana and Institute of Food and Pharmacy, Havana University.

Director of Research. Institute of Marine Sciences, CITMA, Havana, Cuba.

Areas of expertise: Drug-toxicological evaluation of natural and synthetic products. Study of biotransformation mechanisms of xenobiotics, pharmacological interactions. Study of genetic polymorphisms and their impact on human health.

It has more than 70 scientific publications, more than 100 presentations at events and conferences, national awards, national and international project management, graduate thesis and postgraduate training.

Current senior research of two International collaboration projects VLIR of Flemish University of Antwerp, Belgium at ICIMAR and Institute of Oncology in Havana in the field of pharmacogenetic (2016-2020).

Director, Center for Research and Biological Evaluations,

Institute of Pharmacy and Food,

University of Havana, Cuba

Email: gpardo@ifal.uh.cu

H index: 25 / Research gate index: 33,13.

Dr Gilberto L Pardo Andreu holds a PhD degree in Pharmaceutical Sciences. He is Senior Researcher at the Institute of Pharmaceutical and Foods Sciences of the University of Havana (Cuba). He has more than 100 papers in the field of mitochondrial pharmacology. His researches are focused in the elucidation of the pharmaco-toxicological mechanism of bioactive compounds, emphasizing in their effects on mitochondria. In this sense, several promising neuroprotective, anti-diabetic and anti-cancer molecules that modulate mitochondrial function have been discovered in his lab. He also provides continuing education lectures regarding mitochondrial assessment for drug development at pre and post graduate levels. Dr. Pardo Andreu is productive Cuban researcher with a Hirsch index (H index) of 25 and a Research gate index of 33,13.

Birth date: August 2st , 1972.

Head of Pharmacological Research Department

Institute of Tropical Medicine “Pedro Kouri”; Havana, Cuba

Professor of Pharmacology, Institute of Food and Pharmacy,

University of Havana

Personal Phone: 537- 2020011/ Institute Office : 53 7 2553236

Email: lgil@ipk.sld.cu

Biochemist Bachelor, Havana University, Faculty of Biology (09.1990 – 06.1995)

Associate professor (01.2018) Part/time Collaborator of Havana University, Faculty of Pharmacy and Food. Pharmacological Science Philosophical Doctor (PhD) 2004.

Scientific Degree: Senior Investigator (2014)

Head of Pharmacological Research Department, Institute of Tropical Medicine Pedro Kourí.

Elected member of the National Government Board of the Cuban Society of Pharmacology.

She has obtained several national awards from the Cuban Society of Pharmacology and also scientific prize of diverse Congress. She has published up to 66 important contributions related to the pathophysiological characterization, pharmacology and therapeutics of infection diseases in Cuba with H index of 11. Oxidative stress indexes panel have been introducing in her labs and applied in acute and chronic diseases researches. This panel has been used also in post commercialization studies related to adverse reactions reports during drugs schedule. She also contributed to 8 book chapters supported by American Chemical society, London Elsevier, Spain and Italian editors. She has been work evaluating national generics, vaccines candidates and natural products through clinical trials. She is member of Permanent tribunal of Pharmacological Science and tutored several master and bachelors thesis. She has participated in almost 80 workshop and congress, and obtained different recognitions from the Cuban Academy of Sciences.

Current Work: Institute of Pharmaceutical and Food Sciences, University of Havana (http://www.ifal.uh.cu/)

Calle 222 № 2317 e/23 y 31.La Coronela, La Lisa. Habana, Cuba. P.O. Box 13600,

Work Telephone: +53 (7) 2020930

Work Email: marianhc@ifal.uh.cu

Work mobile: +53 (5) 286 9144

Personal email: mhcolina@gmail.com

Dr Marian Hernández Colina is a pharmacist, graduated from Institute of Pharmaceutical and Food Sciences, University of Havana, 1998. She has been working in teaching since then, with more than 20 years of experience in pre and postgraduated teaching of Pharmacology and related fields. Master in Pharmacology, and PhD in Pharmaceutical sciences from University of Havana. Titular professor of Pharmacology. Her focus in research is related to mechanisms of pharmacological or toxicological activities of novel compounds. She has coordinated several postgraduated programs in Pharmacology, published 15 papers in specialized journals, and participated in more than 30 national and international meetings in Pharmacology. Present Dean/Director of the Institute of Pharmaceutical and Food Sciences, University of Havana.

Pharmaceutical Science Degree, 1997

Vice President, Cuban Society of Pharmacology

Member of the Immmunopharmacology Section Board at the International Union of Basic and Clinical Pharmacology (IUPHAR)

 

Current Work: Finlay Vaccine Institute http://www.finlay.sld.cu/                                             

Avenida 27, No. 19805. La Lisa. La Habana, Cuba.

Work Telephone: +53 (7) 271 7911, ext 305; Work mobile: +53 (5) 212 9928

Work Email: mlandys@finlay.edu.cu  / Personal email: mlchovel@gmail.com

Professor Mario Landys Chovel Cuervo is a Pharmacist, graduated from the Cuban Institute of Pharmacy and Food (IFAL), University of Havana, in 1997. His first job was at the Cuban National Drug Regulatory Authority (CECMED), conducting the quality testing of vaccines and blood products for 8 years. Later, he started to work at Finlay Institute of Vaccines (IFV), a Cuban organization dedicated to the Research, Development and Production of Human Vaccines. Currently he was designed as Quality Control Director, but his work for 13 years has been focused in the development and implementation of modern quality control assays for assuring safety and efficacy of vaccines batches. Besides, he has been involved in researching projects against pathogens like Bordetella pertussis, Streptococcus pneumoniae and Neissseria meningitidis, among others. Since 2004 he is acting as Vice-president of the Cuban Society of Pharmacology and member of the Immmunopharmacology Section Board at the International Union of Basic and Clinical Pharmacology (IUPHAR) for 10 years. He has a long experience in the organization of courses and scientific meetings related to vaccines.

Doctor in Medicine (1975),

President of Education Section of Cuban Society of Pharmacology

Senior Professor of Pharmacology, Faculty “10 de Octubre”. University of Medicine of Havana.

1st and 2nd Degree Specialist in Pharmacology, Master in Satisfactory Longevity.

Holder and Founder of the Cuban Society of Pharmacology (SCF), and current President of its Education Section (2012-19). Member of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Latin American Association of Pharmacology (ALF). For her contribution to the development of Pharmacology in Cuba and Latin America she was  awarded with the National Prize of Pharmacology “Dr Francisco J Morón Rodríguez in memoriam” , for the work of a lifetime and contribution to the development of cuban pharmacology (2017) and one special Award from Latinoamerican Association of Pharmacology in the LATINFARMA congress in Havana in 2013. Member of groups of authors of: CD for Teaching of Pharmacology in Cuba by the Primary Health Services, programs of the medical study plan, and fours national texts books for Medical Sciences of Pediatric Pharmacology and Rheumatology. She was honored on two occasions with the National Prize for Pharmacology (2010 and 2015). She participates in multiple National and International scientific events and for her outstanding teaching she receives the distinctions: Medal for Cuban Education (1995), Distinction XX Anniversary of the Havana Medical University (1998), Medal and Diploma of “Illustrious Visitor” University of Santiago de Cali, Colombia (2002), and for the years dedicated to the education and training of health professionals: Jose Tey Medal, (2004), Medal “Frank País” of Second Degree (2013) and “Frank País” of First Degree (2017).

Current Work: Finlay Vaccine Institute http://www.finlay.sld.cu/

Avenida 17 y calle 198. Siboney. Playa. Habana, Cuba. P.O. Box 16017,

Work Telephone: +53 (7) 271 7911, ext 220

Work Email: racevedo@finlay.edu.cu

Personal mobile: +53 (5) 459 8682

Personal email: racevedo7810@gmail.com

Dr Reinaldo Acevedo is a Pharmacist, graduated from the Cuban Institute of Pharmacy and Food, University of Havana, 2002. At this time, he started working at Finlay Institute of Vaccines (IFV), a Cuban organisation dedicated to the Research, Development and Production of Human Vaccines. His work have been focused in the rational design of vaccines and adjuvants based on outer membranes vesicles (OMV) derived from Neissseria meningitidis and other microorganisms. In 2011, Acevedo received his PhD from the Higher Institute of Medical Sciences “Victoria de Girón”, La Havana, with the evaluation of new OMV and OMV derivates (cochleates) as vaccines candidates against Cholera. Since 2012, Dr Acevedo is Head of Research Department at IFV, leading several vaccine projects against pathogens like Mycobacterium tuberculosis, Bordetella pertussis, N. meningitidis but also applications of OMV as adjuvants of vaccine candidates against viral infections, allergies, cancer and addictive drugs. He has received several awards from the Cuban Ministry of Health and the Science and Academy for the novelty of the scientific results. Dr Acevedo also participated as invited expert in International meetings about meningococcal disease and works with the Cuban Societies of Immunology and Pharmacology in the organization of meetings, workshop and Conferences. This work has improved the interchange between prestigious and young researchers worldwide.

Magda Vianneth Solano Roa
Enf. Mg en Farmacología
Miembro ACF
Profesor Asistente
Fundación Universitaria Cafam
E mail: magda.solano@unicafam.edu.co

Enfermera farmacóloga con preparación profesional y experiencia rural en las áreas de urgencias y cuidado hospitalario. Con experiencia laboral en áreas de docencia, clínica y administrativa (especialmente de Auditoria tanto asistencial como Administrativa en Incapacidades, costo médico, revisión y análisis de bases de datos, etc.); con un excelente manejo de software de información. Adicionalmente, en la formación como magister, con las herramientas necesarias para el diseño, dirección y desarrollo de programas de investigación y educación en los centros docentes

Dr. Clara Manrique. MD
Universidad CES
E mail: cimanrique@CES.EDU.CO

Medical surgeon, University of Rosario (Colombia); Clinical Toxicology,University of Antioquia (Colombia),  pharmacology and toxicology  professor at School of Medicine, CES university. Member of the  basic sciences research group, CES university.

Dr. David Galvis Pareja. R.Ph; PhD
Universidad CES
E mail: dagalvis@ces.edu.co

Pharmacist, Universidad de Antioquia (Colombia); Pharmacology PhD, Universidad de Chile (Chile). Pharmacology professor at the Pharmacy program and graduate school at Universidad CES (Colombia). Currently researching in the areas of basic, molecular and clinical pharmacology plus pharmaceutical area. ICIF CES research group.

Dr. Luis Alfonso Laverde Gaona, MD, Esp, MSc.
Fundación Universitaria Navarra – Uninavarra
E mail: luisalfonso110@hotmail.com

Bachelor’s degree in Medicine and Specialist in Epidemiology Surcolombian University; Master’s degree in Pharmacology National University of Colombia. Diploma in therapeutic applications of medical cannabis Rosario University. Director of Basic Sciences – Professor of Pharmacology at the Navarra University Foundation – UNINAVARRA. Pharmacoepidemiological advisor at Willis Towers Watson – Banco de la República. Medical assistance, pharmacologist of the pharmaceutical industry and logistics operators, with pedagogical skills and experience in research on topics related to pharmacology, pharmacovigilance and pharmacoepidemiology, with more than 10 years of experience.a

Dra. Maria Acelia Marrero Miragaya (PhD)

Dra. Maria Acelia Marrero Miragaya (PhD)

(63 yrs. old) is a Cuban research scientist who has majored in the field of clinical trials.

Doctor of Human Medicine and Specialist in General Surgery

Master degree in clinical trials and a Ph.D. in Medical Sciences.

Titular Research, and Professor, University of Havana.

President of Cuban Society of Pharmacology and Member of Latino American Association of Pharmacology (ALF)

Research clinical assistant Group. Clinical trials National Coordinator Center, Havana, Cuba.

Email: acelia@cencec.sld.cu

Ex.  She´s a Titular Professor/Researcher and Principal Investigator Monitor. She has more than 24 years of experiences in clinical trials. She has pioneered the development of different medications in Cuba. A SK produced by recombinant DNA techniques (rSK) has evaluated previously in clinical trials in AMI patients. Her development two natural is products in migraine prevention. Clinical trial phase III. She has concluded several scientific visits to many countries. She has supervised the thesis of, 10 MSc, 2 PhD. and 3 Pharmacology medical specialty. She has served as a referee for 8 doctorate theses, and as a member of examining board for 3 MSc. theses. She has more than 20 publications (journals articles, books chapters), 1 grant patents, more than 20 published abstracts and participation in more than 55 science and technology congresses. Among the distinctions received, she has earned the National Award of the Cuban Academy of Sciences, the Award of the Cuban Ministry of Public Health and several institutional prizes.

Dra. Maria Acelia Marrero Miragaya (PhD)

Dra Yania Suárez Pérez, PhD

President of the National Commission of Career in Pharmaceutical Sciences, Titular professor.

Institute of Pharmacy and Food (IFAL)

University of Havana (UH), Cuba

Email: yaniasp@ifal.uh.cu

Titular professor, she has worked at the Institute of Pharmacy and Foods (IFAL) of the University of Havana for 26 years.  PhD degree in Pharmaceutical Sciences (2005). She has 183 presentations in scientific events, is the author of 66 scientific papers, 3 books and 1 patent. Head of the Discipline of Pharmaceutical Analysis and main teacher of 5 subjects in the career. She teaches in 5 masters courses at the IFAL, and in others countries as guest professor (Ecuador, Honduras). She has been tutor of 87 diploma thesis, 86 theses for master degree and 1 PhD thesis. Has been involved in 4 research projects during the last 5 years. She is member of the Strategic Management Network in Higher Education, is an expert of the National Accreditation Board and is President of the National Commission of Career in Pharmaceutical Sciences. She has received several awards, including the UH Rector’s Award, Distinction for Cuban Education (2017) and the Distinction of the Minister of Higher Education (2019).

Among the distinctions received, she has earned the National Award of the Cuban Academy of Sciences, the Award of the Cuban Ministry of Public Health and several institutional prizes.

Dr. René Delgado Hernández (PhD)

Dr. René Delgado Hernández (PhD)

Sancti Spiritus, Cuba; 23-12-1959

Bachelor Degree in Education in Chemistry, “Enrique Jose Varona” Pedagogical University, Havana (1976-1983)

Bachelor’s Degree in Biochemistry, Faculty of Biology, University of Havana (1983-1987)

PhD in Biological Sciences, 1996.

Academic Titular, Cuban Academic of Science

Current position: Professor and Senior researcher,

Center for Research and Biological Evaluations, Institute of Pharmacy and Food, University of Havana, Cuba

h-index: 35 RG Score: 39.16

Specialized formation in “Immunopharmacology” at Laboratory of Neuroimmunology and mediators of inflammation at Institute for Pharmacological Research “Mario Negri”, Milan , Italy (1990-92). Post graduated position at Internal Medicine Department, Lab of Neuromodulation, Ospedale Maggiore di Milano, University of Milan, Italy (1997). Titular Academic of Cuban Academic of Science since 2010. Head of Biomedical Research Department at Center of Pharmaceutical Chemistry (CQF), (1999-2008). Director of Research at National Center of Clinical Trials of Cuba, (CENCEC) (2008-2009). Director of Research, Center for Pharmaceuticals Research and Development (CIDEM) 2010- 2016. Senior Researcher at Pharmacology Department and in the Center for Research and Biological Evaluation, Institute of Food and Pharmacy (IFAL), Havana University. Senior Professor of Pharmacology, Faculty of Medicine, Medical University of Havana.

He has published more of 190 papers in national al international journals. Active participant in more of 10 international projects in the field of experimental pharmacology and development of new molecules candidates to drugs. Current coordinator of two International projects VLIR of Flemish University of Antwerp, Belgium at CIDEM (2010-2016) and Institute of Pharmacy, Havana University (2016-2020). Author of 8 National Awards of Cuban Academic of Science.

President of Cuban Society of Pharmacology during 15 years (2004-2019). President of Latin-American Association of Pharmacology (2012-2014). Current Past President of both scientific associations. Representative of Cuba and Latin-American at the International Association of Basic and Clinical Pharmacology (IUPHAR).

Carlos Maldonado. MD MSc. 

  • Especialista en microbiología médica 
  • Farmacólogo de la Universidad Nacional.
  • Profesor Dpto. de Farmacia. UN.

Héctor Cacique

Gerente de investigación clínica en Pfizer Argentina

  • Amplia experiencia como monitor, investigador y en aseguramiento de calidad de  estudios multicéntricos fase II  a fase IV, en diversas áreas terapéuticas
  • Carlos Andrés Fiquitiva. Senior Project Manager (Colombia).

 

  • Administrador de Empresas. Universidad de la Salle, Bogotá. 

 

  • 15 años de experiencia combinada en operaciones clínicas y asuntos regulatorios en la industria farmacéutica y CROs.

 

  • Conferencista curso de BPC  – AVANZAR (2016 – 2017).

 

  • Entrenador del Programa para Investigadores desde 2018.

William José Otero Escalante. MD.

Internista

Reumatólogo

Director SERMIVED (Bucaramanga).

Largos años de experiencia en la conducción de estudios clínicos, principalmente en el área de reumatologia.

Claudia Rojas. BSc  

Regional Clinical Site Lead (Pfizer Colombia)

  • Bacterióloga y Laboratorista Clínica. Universidad Colegio Mayor de Cundinamarca.

 

  • 17 años de experiencia en investigación clínica en diversas áreas terapéuticas (oncología, neurología, reumatología, medicina interna, endocrinología y enfermedades infecciosas).

Fredy Jiménez

Químico Farmacéutico.

Maestría Admón Salud.

Country Safety Lead (Colombia and Venezuela).

Cluster Safety Lead for the South Latin America Cluster.

  • Eliana Pulido. Regulatory Affairs Manager (Colombia).

 

  • Química Farmacéutica de la Universidad Nacional.

 

  • Profundo conocimiento y experiencia en el área de asuntos regulatorios y legislación sanitaria. 

 

  • Formación académica y capacitación en BPM y SGC, producción y control de calidad, validación de metodologías analíticas, investigación y desarrollo de medicamentos y cosméticos.
  • Ada Sofia Ramos Doval

    Postgraduate in Semiology and Oral Surgery, Fundacion Universitaria
    San Martin, Bogota.
    Magister in Pharmacology of Cartagena University.
    Current Jobs:
    1. Professor in dental school, Magdalena University, Santa Marta.
    2. Professor in dental school, Metropolitana university,
    Barranquilla.
    3. Semiology and Oral Surgeon, Clinica General del Norte,
    Barranquilla
    E mail: adasofiaramos@hotmail.com
    I has 6 years of experience like university professor, and working as oral surgeon
    more than 8 years in the Clinica General del Norte with hemophilic, oncological
    and cardiac patients.
    NAME YOUR CONFERENCE: INGLES AND SPANISH
    ORAL ADVERSE REACTIONS OF CHEMOTHERAPEUTIC DRUGS AT A
    CANCER INSTITUTION IN BARRANQUILLA-COLOMBIA 2019
    REACCIONES ADVERSAS ORALES DE FÁRMACOS QUIMIOTERAPÉUTICOS
    EN UNA INSTITUCIÓN ONCOLÓGICA DE BARRANQUILLA-COLOMBIA 2019
  • Alberto Alcibíades Salazar Granara

    Doctor in Medicine, Master in Pharmacology, MD & Professor.

    Universidad de San Martín de Porres, Facultad de Medicina Humana (USMP-FMH), Centro de Investigación de Medicina Tradicional y Farmacología (CIMTFAR), Centro de Investigación de Medicina de Altura (CIMA), Unidad Académica de Ciencias Básicas (UACB), Sociedad Peruana de Farmacología y Terapéutica Experimental (SOPFARTEX), Lima, Perú.

    E mail: asalazarg@usmp.pe & alberto.salazar@gmail.com

    CURRICULAR SUMMARY

    Physician at Universidad San Martin de Porres, Perú. Master of Pharmacology at Universidad de San Martin de Porres, Perú. Doctor in Medicine at Universidad de San Martin de Porres, Perú.
    Post Doc in Clinical Research and in Pharmacogenomic at Universidade de Sao Paulo, Brasil. Post Doc in Teratology and Herbal Drug at Universidade de Rio Grande do Sul, Brasil. Head of the Centro de Medicina Tradicional y Farmacologia at Universidad de San Martín de Porres. Head of the Centro de Investigación de Medicina de Altura at Universidad de San Martín de Porres, Director of the Unidad Académica de Ciencias Básicas at Universidad de San Martín de Porres. Member and currently secretary of the Sociedad Peruana de Farmacología y Terapéutica Experimental (SOPFARTEX). Member of the Asociación Peruana Para El Estudio del Dolor (ASPED). Firefighther Sub-Teniente at British Fire Brigade Victoria N°8, Cuerpo General de Bomberos Voluntarios del Perú.

    NAME YOUR CONFERENCE: INGLES AND SPANISH

    ADVANCES IN BIOLOGICAL EFFECTS OF THE PERUVIAN “CHUCHUHUASI” MAYTENUS MACROCARPA (Ruiz &Pav.) Briq: DOSE-RESPONSE ANALGESIC AND ANTIDEPRESSIVE/NEUROLEPTIC EFFECT

    AVANCES EN LOS EFECTOS BIOLÓGICOS DEL “CHUCHUHUASI” PERUANO MAYTENUS MACROCARPA (Ruiz & Pav.) Briq: DOSIS-RESPUESTA ANALGÉSICA Y EFECTO ANTIDEPRESIVO/NEUROLEPTICO

Universidad Nacional de Colombia.

Lab of Pharmacology

Department of Pharmacy

Faculty of Science

Bogotá, Colombia

E mail: alportizsa@unal.edu.co

 

CURRICULAR SUMMARY

Pharmaceutical chemistry, with interest in researching in pharmacology and clinical pharmacy; with experience in researching in pharmacology and regenerative medicine, as well as working in pharmaceutical care and pharmacovigilance. Master of science in pharmacology, currently student in PhD in pharmaceutical sciences, researching with some compounds isolated from natural sources potentially useful in high blood pressure.

 

NAME YOUR CONFERENCE: INGLES AND SPANISH

Vascular interactions of the main metabolites isolated from Croton schiedeanus “almizclillo”.

Interacciones vasculares de los principales metabolitos aislados de Croton schiedeanus “almizclillo”.

 

 

 

 

ABSTRACT

Combination therapy is an effective and therapeutic strategy in clinical practice when the agents improve the pharmacological response. New therapeutics alternatives are researched to reduce the impact of high blood pressure in public health. Natural sources could provide active ingredients that could interact in a synergistic way. Croton schiedeanus, a traditionally specie used in Colombia for antihypertensive purposes, has major metabolites such as 3,7-Di-O-methylquercetin (DMQ) and 3,7,4’-Tri-O-methylquercetin (ayanin), agents with vasorelaxant profile is linked at least in part to the nitric oxide/guanylate cyclase pathway, however their possible synergistic interaction had not been studied until the date. As result, appropriate combination of DMQ and ayanina results in a vasodilator interaction of synergistic type effect that could be useful for therapeutic purposes.

Work Center or Institute or University or Hospital

Universidad Santiago de Cali, Department of clinic

Faculty of Health

University Santiago de Cali, Cali, Colombia

E mail: ana.pardo00@usc.edu.co

 

CURRICULAR SUMMARY (maximun ten lines)

Master in Public Administration, Dentist-DDS with 24 years of practice, teaching at the Santiago de Cali University for over 23 years. Researcher of the Integral Health Research Group – GISI. Author of scientific articles, book chapters, and dissemination material, research project products. Oral speaker and poster at national and international events. Direction of undergraduate and master’s degree work.

…………………………………………………………………………………………………………

NAME YOUR CONFERENCE: INGLES AND SPANISH

EFFECTS ON THE ORAL CAVITY OF MEDICATIONS USED IN PATIENTS WITH PSYCHIATRIC DISORDERS.

 

EFECTOS EN LA CAVIDAD BUCAL DE LOS MEDICAMENTOS UTILIZADOS EN PACIENTES CON  TRASTORNOS PSIQUIÁTRICOS

 

 

 

 

ANEXAR ABSTRACT DE SU PRESENTACION. MAXIMO 300 palabras.

Abstract / Conference (250 a 300 words) ………………..

 

EFFECTS ON THE ORAL CAVITY OF MEDICATIONS USED IN PATIENTS WITH PSYCHIATRIC DISORDERS.

 

Pardo A 1. Pardo I2. Estrada  C3.

¹ Magister / Professor, Universidad Santiago de Cali, Calle 5 # 62-00, Cali, Valle del Cauca, Colombia 2 Doctorate / Professor, Universidad Santiago de Cali, Calle 5 # 62-00, Cali, Valle del Cauca, Colombia

3 Doctorate / Professor, Universidad Santiago de Cali, Calle 5 # 62-00, Cali, Valle del Cauca, Colombia

 

apardo@usc.edu.co

Introduction: Mental disorders are one of the leading causes of morbidity in Colombia, as oral diseases. The different side effects of psychiatric medications in the oral cavity are not well established, studies that address the effects of psychiatric medications in the oral cavity are scarce at the international level and Colombia is no exception; it is therefore important to characterize the effects in the oral cavity of the medications used in patients with psychiatric disorders. Material and Methods: Descriptive cross-sectional study. In 28 institutionalized patients with mental disorder in Colombia. The information was collected by reviewing medical records, determining the effects of medications administered at the mouth level; supported with clinical dental evaluation and interrogation of patients. Results: the largest population was male, with an average age of 39 years. According to the diagnosis, 50% suffer from indifferential schizophrenia and the drugs Biperideno and Piportil are the most consumed. As for the side effects generated in the oral environment are similar. An average of 15.2 missing teeth and a caries prevalence of 86% were determined at the oral assessment. 56% have some type of malocclusion and 64.3% periodontal disease, other pathologies such as xerostomia, torus, gallbladder, tattoo, leukoplakia among others were also identified. 35.7% of patients are smokers and 86% require dental treatment and in all patients there is poor oral hygiene. Conclusion: The oral health status of the population is deficient, leading to a decrease in their well-being, the generalized side effect from the consumption of psychiatric medications was xerostomia.  References:
1. Federación Dental Internacional (FDI. The Challenge of Oral Diseases – A call to global action. Atlas of Oral Health. 2ª ed. Ginebra; 2015. 

  1. Julio Torales, Iván Barrios, Israel González. Oral and dental health issues in people with mental disorders. Medwave2017 Sep;17(8):7045 doi: 10.5867/medwave.2017.08.7045

 

 

Please, Select with X, the area of interest you prefer to present your work.

_____ Basic Pharmacology: FB
__x___ Applied Clinical Pharmacology: FCA
_____ Pharmacoepidemiology and pharmacovigilance: FEV

Dr. Ángel Céspedes Rubio, MVZ, MSc, PhD.

Neurodegenerative Diseases Research Group

Toxicology and Pharmacology Laboratory

Animal Health Department

University of Tolima

E mail: aecesped@ut.edu.co

 

CURRICULAR SUMMARY (maximum ten lines)

I am a veterinarian, and I have a master’s degree in animal health with an emphasis on analytical toxicology, a doctoral degree in basic biomedical sciences with emphasis on Neuroscience, and postdoctoral researching in neuroprotection and nanomedicine as a new alternative to treat ischemic stroke. I have more than 20 years of experience teaching general pharmacology, clinical pharmacology, therapeutics and toxicology in veterinary medical schools and general pharmacology in medical school. Since 2010 I have been researching in preclinical and experimental neuroscience, particularly in ischemic stroke. Currently, I am dedicated to teaching and studying the biological, biochemical and molecular mechanisms of stroke and neurodegenerative diseases in humans.

 

NAME YOUR CONFERENCE: ENGLISH AND SPANISH

CURSO PRECONGRESO; FARMACOLOGIA VETERINARIA

Rationale treatment of chronic inflammatory pain in aged dogs

Tratamiento racional del dolor inflamatorio crónico en perros de edad avanzada

CONFERENCIA: Statins in polymeric nanosuspension associate to small peptides protect neuronal cultures from oxygen-glucose deprivation (OGD) model

La atorvastatina en nanosuspensión polimérica asociada a péptidos pequeños, protege los cultivos neuronales en un modelo de privación de oxígeno-glucosa (OGD)

Dr. Angélica Castellanos Sánchez, VMD,PhD

Escuela de Bacteriología y Laboratorio Clínico de la Universidad del Valle/ Facultad de Ciencias Básicas USACA

E mail: angelica.castellanos@univalle.edu.co

            ancastellanosan@gmail.com

 

CURRICULAR SUMMARY (maximun ten lines)

VMD, PhD, Microbiologist, obtained PhD at Faculty of Health at Universidad del Valle in 2012. Professor of Immunology and Cellular and Molecular Biology.

Expertise for more than 10 years in infection diseases, immunology and vaccinology, as researcher involved in pre-clinical and clinical trials, especially in Primate Center and Cellular Laboratory at Malaria Vaccine and Drug Development Center (MVDC). These experiences have been associated to understanding the immune protective mechanisms related host, vector (mosquitos) the immunobiology, natural Immunity and Pathophysiology of transmission vector infection like malaria, Dengue, Zika, Chikungunya.

Other studies involve, characterization of candidate vaccine, B and T cell epitope mapping, immuno-epidemiological studies, preclinical and clinical studies, developed a reliable method to produce sporozoites and an infectious challenge, results that provided knowledge and advances in the mechanism to achieve control and elimination of transmission vector diseases.

 

NAME YOUR CONFERENCE: ENGLISH AND SPANISH

Transmission blocking strategies for vector-borne diseases

Estrategias de bloqueo de la transmisión de enfermedades vectoriales

Carlos Andrés Pineda Cañar

Médico y Cirujano

Especialista en Medicina Familiar

Magister en Educación Superior

Profesor Titular – Departamento de Medicina Familiar – Universidad del Valle

Director del Programa de Medicina y Cirugía – Universidad del Valle

Entrenamiento en Diabetes Royal College of General Practitioner – NICE (National Instutute for Clinical Excelence)

Miembro del grupo de trabajo en Prevención Cuaternaria de la Confederación Iberoamericana de Medicina Familiar

Dr. Catalina Estrada González.

Work Center or Institute or University or Hospital

Universidad Santiago de Cali, Department of public health

Faculty of Health

University Santiago de Cali, Cali, Colombia

E mail: catalina.estrada00@usc.edu.co

.

 

CURRICULAR SUMMARY (maximun ten lines)

Doctorate in Education. Master in Higher Education. Master in Administration, Surgical Instrumenter. Full-time professor at the University of Santiago de Cali, School of Health, Department of Public Health.

Among his publications are the training of the university professor in the areas of health, humanities and administration. A biographical look (2017). Power and control relationships expressed in the pedagogical discourse of teachers in the professional cycle of a surgical Instrumentation program in Colombia (2015), the books Occupational Risk Control in Health Training Practices (2017), Healthy University: an interdisciplinary strategy for the construction of a healthy environment (2018), Disability and inclusion in the University (2018) among others. Member of the research group in Education and Health – GINEYSA category B in Colciencias.

…………………………………………………………………………………………………………

NAME YOUR CONFERENCE: INGLES AND SPANISH

ADVERSE EVENTS IN DENTAL PROCEDURES RELATED TO MEDICATION.

 

……………..…………………………………………………………………………

EVENTOS ADVERSOS EN PROCEDIMIENTOS ODONTOLÓGICOS RELACIONADOS CON LA MEDICACIÓN.

 

ANEXAR ABSTRACT DE SU PRESENTACION. MAXIMO 300 palabras.

ADVERSE EVENTS IN DENTAL PROCEDURES RELATED TO MEDICATION.

 

 

Abstract / Conference (250 a 300 words) ………………..

Estrada C1. Pardo I 2

¹ Doctorado / Magister / Profesor, Universidad Santiago de Cali, Calle 5 # 62-00, Cali, Valle del Cauca, Colombia

2 Doctorado / Magister /Profesor, Universidad Santiago de Cali, Calle 5 # 62-00, Cali, Valle del Cauca, Colombia

catalina.estrada00@usc.edu.co    ivanoba.pardo00@usc.edu.co

 

Introduction: The adverse event (E.A) is the “result of medical care that causes harm unintentionally.” In Colombia, the concept is framed in the context of patient safety policy, whose main intention is to offer safe medical care.

During the dental procedure adverse events due to the use of medications are presented, therefore the objective of the present investigation was to identify the causes of the adverse events related to the medications in the years 2015 to 2018 at a dental clinic in the city of Cali Colombia.

 Material and Methods: A retrospective descriptive study that took forty-two (42) EA records related to medication in a Cali dental clinic between 2015 and 2018. For the choice of records, the inclusion and exclusion criteria were taken into account. , for the first reports of patients throughout the life cycle, corresponding to all dental procedures. In the exclusion criteria, the E.A report formats with an empty data proportion greater than 10%. The information was collected through a format based on the EA notification instrument of the National Institute of Food and Drug Surveillance INVIMA 2014. The information was processed in Epi info version 7.2.0.1. To carry out the study, authorization was obtained from the scientific committee of the institution. Results : Among the most frequent causes of adverse events related to medication were: medication omission 63%, incorrect dose 13%, incorrect medication 8%, reaction to medication 8%, administration error 5% and medication in wrong patients 3 %. The unsafe actions identified were the lack of knowledge of dentists for the administration of medications, diagnostic errors, failures in the identification of medications with similar names and appearance.  Conclusion: Adverse events can be prevented by implementing the pharmacovigilance program in dental clinics as part of the patient’s safety policy.  References:

Estrada González C, González Restrepo LD. Adverse events related to the surgical act in a third level health institution. Cuban Journal of Public Health [Internet magazine]. 2018 [cited 2018 Jul 30]; 44 (3): [approx. 0 p.]. Available in: http://www.revsaludpublica.sld.cu/index.php/spu/article/view/998

 

Daza Aliatis Juan Manuel, Jimbo Mendoza Julio Cesar, obeys Macías Gisela Maribel, Toro Castillo Mercedes. Adverse events in dental practice. MEDISAN [Internet]. 2015 Sep [cited 2019 Aug 13]; 19 (9): 1158-1162. Available in: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192015000900013&lng=es.

 

 

 

Please, Select with X, the area of interest you prefer to present your work.

_____ Basic Pharmacology: FB
__x___ Applied Clinical Pharmacology: FCA
_____ Pharmacoepidemiology and pharmacovigilance: FEV

 

 

 

 Dr. AUDREY MARY MATALLANA  MD

Pediatra Endocrinóloga , Hospital Universitario del Valle

Departamento de Pediatria

Escuela de Medicina

Universidad del Valle, Cali , Colombia

E mail:audrey.matallana@correounivalle.edu.co

Medico y cirujano de la Universidad Del Valle.

Especialista en Pediatria universidad del Valle.

Fellow de Endocrinologia Pediatrica de la Universidad de Alabama en Birmingham.

Miembro de Numero de la Asociacion Colombiana de Endocrinologia  ACE.

Miembro de Numero del Colegio Asociacion de Endocrinologia Pediatrica ACEP.

Miembro de la Sociedad Latinoamericasa de Endocrinologia Pediatrica SLEP.

Expresidente de la ACEP y de la SLEP.

Profesora Asociada del Departamento de Pediatria de la Universidad del Valle.

Endocrinologa Pediatra del Hospital Universitario del Valle.

Pediatra Endocrinologa con 26 años de experiencia en practica clínica y docente, past President del Colegio Asociacion Colombiana de Endocrinologia Pediatrica y de la Sociedad Latinoamericana de Endocrinologia Pediatrica

NAME YOUR CONFERENCE: INGLES AND SPANISH

1-Reemplazo de Esteroides sexuales en Pacientes con Sindrome de Turner: Sexual Steroid Treatment in Turner Syndrome Patients

2-Tratamiento de la Diabetes Neonatal:Neonatal Diabetes Treatment.

ANEXAR ABSTRACT DE SU PRESENTACION.

 

 

CURRICULAR SUMMARY (maximun ten lines)

Celine obtained her Master’s degree in Cosmetic Science from the University of Paris Sud in France. She started her carrier in Ireland (Oriflame cosmetics), where she helped set up a clinical testing facility internal to the company and worked on the creation of innovative test methods for cosmetic products. In 2011, after 4 years in Ireland she moved to Thailand and became Clinical Studies Director in Spincontrol Asia, an independent cosmetic CRO, supporting the technical, sales and IT department.  During the same period she helped develop the Indonesian branch from the same company and she still supports this laboratory in the technical and Quality Assurance areas. Last year, after more than 6 years spent in Thailand, the opportunity was presented to her to move to Colombia to support cosmetic companies as freelance, in the area of clinical testing.

…………………………………………………………………………………………………………

NAME YOUR CONFERENCE: INGLES AND SPANISH

CONFERENCE 1:

STUDIES AND METHODS FOR THE EFFICACY EVALUATION OF DERMATOLOGICAL PRODUCTS

Estudios y metodologías para la evaluación de eficacia de productos dermatológicos

CONFERENCE 2:

ASSESSMENT OF THE SAFETY OF DERMATOLOGICAL PRODUCTS

Valoración de la seguridad de productos dermatológicos

 

ANEXAR ABSTRACT DE SU PRESENTACION. MAXIMO 300 palabras.

 

 

“STUDIES AND METHODS FOR THE EFFICACY EVALUATION OF DERMATOLOGICAL PRODUCTS”.

Celine Blanche.  BSc, MSc I&R Productos Cosméticos. CB Consulting SAS.  Francia.

Cosmetic/ dermatological products become more and more effective at performing up to their claims, narrowing the frontier between cosmetic/dermatological products and drugs. Regulatory bodies on the other hand are becoming stricter and stricter to ensure consumers’ safety as well as the respect of those claims made by cosmetic companies. Several parameters need to be taken into account when setting up a clinical study to prove the efficacy of a dermatological product, as those can impact the final study results. The choice of the method of evaluation can also impact on the final claims as methods are not all equivalent and might measure a different aspect of a given skin property. This review aims at making the audience aware of some of those parameters that should be considered before starting a clinical study, with a special focus on studies performed in South America. The presentation will also show several methods available for a given claim and how to link clinical study results with marketing claims.

 

 

 

 

 

“ASSESSMENT OF THE SAFETY OF DERMATOLOGICAL PRODUCTS”.                                                                                                         Celine Blanche. BSc, MSc I&R Productos Cosméticos. CB Consulting SAS.  Francia.

While the balance benefit/ risk is part of the evaluation of a new drug in development, any cosmetic/ dermatological product put on the market should demonstrate that it is actually perfectly safe to be used by targeted consumers. Depending on the country where the new product will be launched/ sold, different safety tests need to be performed by manufacturers, even though most regions of the world require similar tests to be performed as part of confirming the safety of a new product. This presentation will review those tests required for dermatological products.

Dr. CRISTINA BOHÓRQUEZ MORENO, Enf MSc

Professor Faculty of Health sciences, Nursing School

Rafael Nuñez University Corporation in Barranquilla, Colombia

E mail: cristina.bohorquez@curnvirtual.edu.co

 

CURRICULAR SUMMARY (maximun ten lines)

Ex.  I am nurse of Cartagena University, Colombia and master’s degree in pharmacology and Cartagena University. I worked and nursing Faculty of Cartagena University in research department, now I am a professor at the Rafael Nuñez University Corporation in Barranquilla, Colombia………………………………………………………………………

NAME YOUR CONFERENCE: INGLES AND SPANISH

…… IN VITRO INHIBITION OF ANGIOTENSIN-CONVERTING ENZYME WITH EXTRACTS OF JATROPHA GOSSIPYFOLIA AND HELIOTROPIUM INDICUM …………………………………………………………………………………………………………… INHIBICIÓN IN VITRO DE ENZIMA CONVERTIDORA DE ANGIOTENSINA CON EXTRACTOS DE JATROPHA GOSSIPYFOLIA Y HELIOTROPIUM INDICUM ………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

SUMMARY of Professional Experience (maximum ten lines)

Ex.  David Johnston-Monje is an impact-oriented biologist with more than 15 years of research experience in agriculture, plant, microbial and molecular sciences. His professional interest centers on the study of plant genetics and plant microbial ecology to help discover answers to humanity’s challenges in agriculture and biodiversity conservation. His research has resulted in 10 publications and 13 published or filed patents, and contributed to the founding of two startup companies and two academic labs. ……………………………………………………………………………………………………..

NAME YOUR CONFERENCE: INGLES AND SPANISH

A Model of Discovery and Development of Probiotics Products: Establishing a paradigm, effective bioprospecting, relevant screening and successful deployment ………………………………………………………………………………………………………… Un modelo de descubrimiento y desarrollo de productos probióticos: establecimiento de un paradigma microbiano, bioprospección efectiva, tamizaje relevante y despliegue exitoso

 

SUMMARY of Professional Experience (maximum ten lines)

Ex.  David Johnston-Monje is an impact-oriented biologist with more than 15 years of research experience in agriculture, plant, microbial and molecular sciences. His professional interest centers on the study of plant genetics and plant microbial ecology to help discover answers to humanity’s challenges in agriculture and biodiversity conservation. His research has resulted in 10 publications and 13 published or filed patents, and contributed to the founding of two startup companies and two academic labs. ……………………………………………………………………………………………………..

NAME YOUR CONFERENCE: INGLES AND SPANISH

A Model of Discovery and Development of Probiotics Products: Establishing a paradigm, effective bioprospecting, relevant screening and successful deployment ………………………………………………………………………………………………………… Un modelo de descubrimiento y desarrollo de productos probióticos: establecimiento de un paradigma microbiano, bioprospección efectiva, tamizaje relevante y despliegue exitoso

Dr. Diego Fernando Mejía Carmona, PhD

Universidad Nacional de Colombia, Sede Palmira

Department of Basic Sciences,

Palmira, Colombia

E mail: dfmejiac@unal.edu.co

 

CURRICULAR SUMMARY

He is a Biologist with strong emphasis in Genetics, masters studies in Biochemistry, a master degree in Biotechnology, and a PhD degree in Biomedical Sciences. At present, he is working in Protein engineering and protein bioinformatics for use in biomedicine and in environmental issues. He has long experience in molecular biology and bioinformatics and their application in protein redesign. He is professor at Universidad Nacional de Colombia, and a member of the research groups of Bioinformatics and Biocomputing at Universidad del Valle, the research group on Bioprosecting and Biotechnology at Universidad Nacional, and the American Society of Biochemistry and Molecular Biology.

Molecular evolution and bioinformatics tools for producing recombinant proteins to be used in medical and pharmaceutical applications.

Herramientas de la evolución molecular y la bioinformática para producir proteínas recombinantes para su uso en aplicaciones médicas y farmacéuticas.

 

Proteins realize most of the molecular tasks in the cell. Because of it, redesign proteins implies a high potential for pharmaceutical products. Here we present molecular evolution and bioinformatics tools for redesigning proteins suitable for evaluating new candidate molecules to become antibiotics, and proteins for regenerating bone in fractures.

Dr. EDISON CASTRO VELASCO, DDS

Work Center or Institute or University or Hospital …..

Faculty of Health, Program of Dentistry,

Santiago de Cali University, Cali, Colombia

E mail: ecastro@usc.edu.co

 

Dentist, specialist in Maxillofacial Surgery, graduated from the Javeriana University of Bogotá, with 25 years of clinical experience and 21 years of experience in teaching pharmacology at the Santiago de Cali University. Member of the Colombian Association of Oral and Maxillofacial Surgery, Delegate of Education in the Colombian Association of Dental Faculties (ACFO).

Odontólogo, especialista en Cirugía Maxilofacial, egresado de la Universidad Javeriana de Bogotá, con 25 años de experiencia clínica y 21 años de experiencia en la enseñanza de farmacología en la Universidad de Santiago de Cali. Miembro de la Asociación Colombiana de Cirugía Oral y Maxilofacial, Delegado de Educación en la Asociación Colombiana de Facultades Dentales (ACFO).

Dr. Javier Orozco

Work ACOMFAR SAS

Santiago de Cali University, Public Health Department …

Faculty of Health

University of Santiago de Cali, Cali, Colombia

Email:Javier.orozco03@usc.edu.co

 

CURRICULAR SUMMARY (maximun ten lines)

  1. Master in Public Management(e), Universidad Santiago de Cali, at present
  2. Health Auditor, Universidad del Valle, april 2017
  3. Verifier in health qualification standards, Universidad del Valle, december 2015
  4. Regent of Pharmacy, Santiago de Cali University, april 2012
  5. Public Health Specialist, Universidad del Valle, november 2006
  6. business administrator, Universidad del Valle, december 2002
  7. Member of the board of directors of ASORESVALLE, Association of Regents of the Valle
  8. ABBOTT Laboratory Pharmaceutical Lecturer and Trainer
  9. Legal Representative of ACOMFAR SAS, Training and management company in the pharmaceutical sector

 

NAME YOUR CONFERENCE: INGLES AND SPANISH

Importance of molecular stability in pharmaceutics establishments and their therapeutic action

Importancia de la estabilidad molecular en los establecimientos farmacéuticos y su acción terapéutica.

Orozco J.1, Bermeo M.2

 

ANEXAR ABSTRACT DE SU PRESENTACION. MAXIMO 300 palabras.

Abstract / Conference (250 a 300 words) ……

The abstract was already sent.

IMPORTANCE OF MOLECULAR STABILITY IN PHARMACEUTICS ESTABLISHMENTS AND THEIR THERAPEUTIC ACTION

Orozco J1 , Bermeo M2

1 Especialista / Profesor, Universidad Santiago de Cali, Calle 5 # 62-00, Cali, Valle del Cauca, Colombia

2 Magister / Profesor, Universidad Santiago de Cali, Calle 5 # 62-00, Cali, Valle del Cauca, Colombia

 

Introduction:  Recent studies have shown the decrease in the effectiveness of medicines when they are exposed to unfavorable conditions within the framework of the opening criteria of pharmaceutical establishments. These economic entities do not have an adequate infrastructure and equipment that guarantees the good practices of drug storage, which generates molecular instability, affecting the quality of the drug and its therapeutic action in the users’ organism.  Material and Methods:  This paper is theoretical, where the information collected through the observation, verification and evaluation of outpatient pharmaceutical establishments nationwide, the findings related to the change are shared based on the work experiences of the exhibitor obtained during 16 years. in the molecular stability of drugs as a result of processes of acquisition, reception, storage and distribution. During the presentation, attendees will be able to interact with the speaker from open-ended questions that allow clarifying specific concerns.  Results:  At the end of the presentation, attendees will have theoretical-practical tools that allow them to recognize the importance of good storage practices, the impact on the molecular stability of medications and their therapeutic effect on the users to whom it is administered; since the supply of drugs with molecular alteration can cause alterations in the organism, leading to resistance to these active principles, which means that medical personnel must rethink their treatment with much more concentrated and molecularly toxic drugs. Conclusion:  During my experience in the verification and audit of outpatient pharmaceutical establishments, the lack of education and accompaniment by the health control entities as well as the infrastructure and provision for the storage of medications and medical devices could be evidenced.

MSc Dolly Villegas Arenas

Work Center or Institute or University or Hospital …..

Ex: Lab of ……. , Department of Nursing………

Faculty of Health

University of Santiago de  Cali, Colombia

E mail: dolly.villegas00@usc.edu.co

Dolly Villegas Arenas2

1Enf. MsC. Profesora, Programa Académico de Enfermería, Facultad de Salud, Universidad Santiago de Cali. Calle 5 # 62-00, Cali, Valle del Cauca, Colombia

2Enf. MsC. Profesora Cátedra, Programa Académico de Enfermería, Facultad de Salud, Universidad Santiago de Cali. Calle 5 # 62-00, Cali, Valle del Cauca, Colombia

Dra. Helen Carolina Patiño MD.

Hospital Universitario del Valle.

Endocrinología Pediátrica

Universidad de Buenos Aires, Argentina

E mail: hellemcita@hotmail.com

CURRICULAR SUMMARY (maximun ten lines)

 

Medico de la Universidad Santiago de Cali

Especialista en Pediatría de la Universidad de Buenos Aires en el Hospital Juan P. Garrahan.

Especialista en Endocrinología de la Universidad de Buenos Aires en el Hospital Juan P. Garrahan.

Endocrinóloga Pediatra del Hospital Universitario del Valle

 

NAME YOUR CONFERENCE: INGLES AND SPANISH

Uso de Bifosfonatos en Niños y Adolescentes

Bisphosphonate Therapy in Children and adolescents

 ANEXAR ABSTRACT DE SU PRESENTACION. MAXIMO 300 palbras.

 

La osteogenesis imperfecta (OI) es una enfermedad genética, que hace parte del grupo de enfermedades huérfanas, se caracterizan por un aumento en la fragilidad ósea, disminución de la masa ósea y susceptibilidad a fracturas múltiples esporádicas. No contamos con datos de prevalencia en nuestro país hasta el momento; en la literatura encontramos un estimado 1-5/10000 en el mundo. Se han identificado 4 tipos de Osteogenesis Imperfecta, los cuales tienen diversidad en su expresión clínica, el 95% de los casos es causada por mutaciones en los genes COL1A1 y COL1A2 (17q21.33-7q21.3) que codifican par alas cadenas alfa de colágeno tipo I. Los niños y adolescentes con Osteogenesis Imperfecta experimentan dolor en diversos lugares, este puede fluctuar de intensidad pero siempre es referido  como incapacitante y limitante para su optima calidad de vida.

El tratamiento con infusión de  Bifosfonatos  nitrogenados endovenoso, como el Pamidronato y  Acido Zoledronico cuyo uso ha sido aprobado en osteoporosis y al ser utilizados en osteogenesis imperfecta disminuyen la resorción ósea, incrementan el grosor de la cortical reduciendo la taza  fracturas de huesos largos y dolor óseo, optimizando morfología y fortaleza de las vertebras mejorando su calidad de vida, es decir se han reportados beneficios con el uso de los Bifosfonatos pero aun no cambios en la historia natural de la enfermedad.

  • CURRICULAR SUMMARY (maximun ten lines)
    Pharmacist and MSc in Pharmacology, PhD in Pharmacological Innovation from the
    Université Paul Sabatier Toulouse III – Institut de Recherche pour le Développement,
    Thesis Très Honorable 2007. He obtained the National Prize of Pharmacology and
    Therapeutics in 2003 and 2017. Visiting Professor at Federal University of Minas Gerais
    2008. Worked at the Institute of Immunology H.S.J.D. 1994-1996, later he was Temporary
    Consultant of the Special Program for Research and Training in Tropical Diseases
    TDR/WHO 1996-1999. Since 2000 he is linked to National University of Colombia, he was
    Academic Vice-Dean Faculty of Sciences 2011-2018 and is currently researcher of the
    Group: Pharmacology of traditional and popular medicine Fametra (COLCIENCIAS
    Category B) has national and international publications in the field of experimental
    pharmacology, ethnopharmacology and natural products. orcid.org/0000-0002-6055-0501.
    NAME YOUR CONFERENCE: INGLES AND SPANISH
    Ethnopharmacology with social responsibility
    …………………………………………………………………………………………………………
    Etnofarmacología con responsabilidad social
    ________________________________________________________________________
  • ANEXAR ABSTRACT DE SU PRESENTACION. MAXIMO 300 palbras.
    El uso de productos naturales con fines terapéuticos es tan antiguo como la civilización
    humana, que durante mucho tiempo tuvo únicamente en ellos la herramienta para el
    tratamiento de las enfermedades. A lo largo de la historia las diferentes sociedades, han
    adquirido y conservado conocimientos necesarios para identificar y tratar las
    enfermedades, estos conocimientos son transmitidos por tradición oral de generación en
    generación, este conjunto de conocimientos usos y actitudes constituye el conocimiento
    tradicional.
    La etnofarmacología es el estudio científico interdisciplinario de los productos naturales
    relacionados con los conocimientos y prácticas que diferentes culturas han empleado con
    propósitos de diagnóstico, prevención o curación de las enfermedades. La
    etnofarmacología involucra dos aproximaciones disciplinarias; la etnología relacionada
    con el acercamiento científico a la cultura o sociedad de los pueblos y la farmacología
    relacionada con el estudio científico de los remedios y su efecto sobre organismos vivos,
    especialmente el efecto biológico de fármacos así como la identificación, clasificación
    (biológica y química) de las materias de origen vegetal y sus componentes activos y su
    efecto sobre organismos vivos.
    Reconociendo la importancia de la medicina tradicional y de la valoración de la diversidad
    biológica de nuestros países y sus posibles aplicaciones en salud pública (y
    eventualmente en la industria farmacéutica); esta conferencia busca incentivar en los
    asistentes el interés por rescatar y documentar la herencia cultural y desde un punto de
    vista crítico abordar temas relacionados con la etnobiología, etnomedicina,
    etnofarmacología, protección de la biodiversidad, acceso a recursos genéticos y
    conocimiento tradicional y distribución justa y equitativa de los beneficios que se deriven,
    así como dar a conocer algunas experiencias de investigación en este campo en
    Colombia y de esta manera contribuir al mejoramiento de la salud pública de la población.
    Use of natural products for therapeutic purposes is as old as human civilization, which for
    a long time had only in them the tool for the treatment of diseases. Throughout history
    different societies have acquired and preserved the knowledge necessary to identify and
    treat diseases, this knowledge is transmitted by oral tradition from generation to
    generation, this set of knowledge uses and attitudes constitutes traditional knowledge.
    Ethnopharmacology is the interdisciplinary scientific study of natural products related to
    the knowledge and practices that different cultures have used for purposes of diagnosis,
  • prevention or cure of diseases. Ethnopharmacology involves two disciplinary approaches;
    ethnology related to the scientific approach to the culture or society of peoples and
    pharmacology related to the scientific study of remedies and their effect on living
    organisms, especially the biological effect of drugs as well as the identification,
    classification (biological and chemical) of materials of plant origin and their active
    components, including their effect on living organisms.
    Recognizing the importance of traditional medicine and the valuation of the biological
    diversity of our countries and its possible applications in public health (and eventually in
    pharmaceutical); This conference seeks to encourage attendees interest in rescuing and
    documenting cultural heritage and from a critical point of view address issues related to
    ethnobiology, ethnomedicine, ethnopharmacology, biodiversity protection, access to
    genetic resources and traditional knowledge and fair and equitable distribution of benefits
    derived, as well as to share some research experiences in this field in Colombia and thus
    contribute to improving public health of the population.
GILBERTO AMED CASTILLO BARRIOS
Especialista en Medicina Interna y Cardiología
Ex-vicepresidente de la Sociedad Colombiana de Cardiología
Coordinador del Comité de Trombosis y Anticoagulación de la
Sociedad Colombiana de Cardiología
Director Científico de Cardioprevent IPS y cardiólogo clínico de
Centro Médico Imbanaco en Cali.
RIESGO CARDIOVASCULAR: PREVENCIÓN FARMACOLÓGICA
GILBERTO AMED CASTILLO BARRIOS
Especialista en Medicina Interna y Cardiología.
Ex-vicepresidente de la Sociedad Colombiana de Cardiología.
Coordinador del Comité de Trombosis y Anticoagulación de la Sociedad Colombiana de Cardiología.
Director Científico de Cardioprevent IPS y cardiólogo clínico de Centro Médico Imbanaco en Cali.
Las enfermedades cardiovasculares continúan siendo la causa número 1 de muerte en todo el mundo,
por encima del cáncer y las enfermedades respiratorias. Diferentes tratamientos farmacológicos se han
desarrollado en los últimos años para reducir la probabilidad de nuevos eventos en aquellos pacientes
que ya han sufrido un infarto cardiaco previo o han tenido un ataque crebreovascular. En esta
conferencia se revisará la más reciente evidencia acerca de las terapias disponibles para reducir nuevos
eventos en pacientes con riesgo cardiovascular muy alt

 Dra. LINA MARIA PEÑA ACEVEDO, MD, MSc

Associated Professor

Department of Pharmacology and Toxicology.

Faculty of Medicine

University of Antioquia, Medellín, Colombia

E mail: lina.pena@udea.edu.co 

 

CURRICULAR SUMMARY (maximun ten lines)

I am a clinical toxicologist. Besides, also I have a master in occupational health and master in environmental toxicology. For more than 10 years I have been an associate professor at the Faculty of Medicine of the University of Antioquia, in the Department of Pharmacology and Toxicology, working with undergraduate students of medicine and postgraduate students of medical toxicology, emergency medicine and psychiatry, in the care of intoxicated patients at the University Hospital San Vicente de Paul in Medellin – Colombia.

I have great experience in the treatment of very serious intoxicated patients, especially poisoning by poisonous animals, pesticides and drugs.

I also work in the poison center of the Faculty of Medicine of the University of Antioquia, in the care of intoxicated patients.

 

NAME YOUR CONFERENCE: INGLES AND SPANISH

Reacciones adversas al uso de antivenenos y fármacovigilancia.

Adverse reactions to snake antivenom, and their drug surveillance

 

ANEXAR ABSTRACT DE SU PRESENTACION. MAXIMO 300 palbras.

 

Abstract / Conference (250 a 300 words)

El accidente ofídico ha sido reconocido por la Organización Mundial de la Salud, como una enfermedad desatendida. En Colombia ocurren cada año alrededor de 5000 mordeduras por serpiente, siendo el tercer país en incidencia en Latinoamérica luego de México y Brasil.  El antiveneno es la terapia más efectiva para el tratamiento del envenenamiento secundario a mordeduras de serpientes, no obstante según los datos del Instituto Nacional de Salud para el 2017, y con base en la clasificación de gravedad, en nuestro país el 13 % de los casos clasificados como moderados y graves, no recibió antiveneno y al 9,4 % de los casos clasificados como no envenenamiento si se les administró. Adicionalmente se observó que en el 8,0 % de los casos en los que se administró suero, se observó algún tipo de reacción, el 51 % correspondió́ a reacciones generalizadas.

El acceso a los antivenenos puede ser difícil, por aspectos como costos, ubicación geográfica, condiciones locativas de las instituciones de salud, entrenamiento del personal sanitario, aspectos socioculturales, calidad del producto. Estas situaciones pueden llevar a un uso inadecuado del medicamento, lo cual podría de alguna manera incidir en la efectividad o en la aparición de eventos relacionados con su uso.

La farmacovigilancia ayudaría a un mejor conocimiento de esta problemática, y de esta manera contribuir a mejorar la calidad, efectividad y seguridad de los antivenenos.

 

 

Dra Leidy Aristizabal Gomez

Medico internista y geriatra – Universidad de Caldas

Master en Cuidado Paliativo – Universidad de la rioja

Cali, Colombia

E mail: leidyjhoana182@gmail.com

 

Egresada de la universidad de caldas en Medicina interna y geriatria hace 2 años desde entonces dedicada al manejo del anciano en contexto hospitalario y cuidado agudo incluyendo el anciano en cuidados paliativos, uso de la via subcutanea y por lo tanto manejo amplio de la farmacologia en el anciano. Ademas me desempeño como docente en geriatria con la Universidad libre de Cali en el postgrado de medicina interna y psiquiatria.

NAME YOUR CONFERENCE: INGLES AND SPANISH

Rational use of Antibiotics in the elderly

Uso racional de antibioticos en el anciano

 

ANEXAR ABSTRACT DE SU PRESENTACION. MAXIMO 300 palabras.

 

 

 

 

RATIONAL USE OF ANTIBIOTICS IN THE ELDERLY

Leidy Aristizabal Gomez (MD, MSc)

Medico internista y geriatra – Universidad de Caldas, Master en Cuidado Paliativo – Universidad de la Rioja, Cali, Colombia

E mail: leidyjhoana182@gmail.com

 

The elderly population is increasing worldwide and by 2050 it’s expected that over 2 billion

will be aged 60 years and older. The elderly may be at increased risk of bacterial infections in comparison with younger adults, in relation not only to ageing per se, but also to multiple underlying predisposing diseases. The most frequent bacterial infections in this subpopulation are urinary tract infections, pneumonia and skin and soft tissue infections.

 

It has been shown that the use of antimicrobial agents is quite remarkable among elderly

patients, especially among those who are institutionalized.

 

Appropriate management of antibiotics is mandatory nowadays due to the worrisome increase of bacterial resistance rates worldwide. However, finding the right balance between efficacy, safety and tolerability when using antimicrobials in this patient population is quite difficult for a number of reasons. Ageing is characterized by significant changes in body tissue composition and by a progressive physiological decline of several organ functions.

 

Additionally, the rather frequent presence of comorbidities in the elderly may require multiple drug coprescriptions. Polypharmacy, in turn, may favor drug-drug interactions and potentially inappropriate prescriptions. Nothworthy, the use of some antimicrobials may be associated with severe adverse events in this population, especially when in presence of co-medications and/or of co-morbidities

 

The question is more difficult in patients with severely reduced quality of life or in patients with terminal dementia. The considerations here are two-fold: reduced benefit and increased cost. Such patients gain less from antibiotic treatment proportional to the decline in functional capacity, cognitive function and quality of life. As such patients are frequently exposed to the healthcare system they are more likely to carry multidrug-resistant bacteria, necessitating broader-spectrum empirical antibiotic treatment with higher ecological costs.

 

RATIONAL USE OF ANTIBIOTICS IN THE ELDERLY

Leidy Aristizabal Gomez (MD, MSc)

Medico internista y Geriatra – Universidad de Caldas, Master en Cuidado Paliativo – Universidad de la Rioja, Cali, Colombia

 

 

 

 

 

 

 

 

La población de ancianos está aumentando en todo el mundo y para 2050 se espera que más de 2 billones tendrá 60 años o más. Los ancianos pueden tener un mayor riesgo de infecciones bacterianas en comparación con los adultos más jóvenes, en relación no solo con el envejecimiento per se, sino también por las múltiples comorbilidades subyacentes. Las infecciones bacterianas más frecuentes en esta subpoblación son infecciones del tracto urinario, neumonía e infecciones de piel y tejidos blandos.

Se ha demostrado que el uso de antibióticos es frecuente entre los ancianos, especialmente entre aquellos que están institucionalizados.

El manejo apropiado de los antibióticos es obligatorio hoy en día debido al aumento preocupante de las tasas de resistencia bacteriana en todo el mundo. Sin embargo, encontrar el equilibrio correcto entre eficacia, seguridad y tolerabilidad cuando se usan antimicrobianos en esta población de pacientes es bastante difícil por varias razones. El envejecimiento se caracteriza por cambios significativos en la composición del tejido corporal y por un declive fisiológico progresivo múltiples funciones orgánicas.

Además, la presencia de múltiples comorbilidades en los ancianos lleva a que requieran múltiples prescripciones de medicamentos. La polifarmacia a su vez puede favorecer las interacciones farmacológicas y las prescripciones potencialmente inapropiadas. El uso de algunos antimicrobianos puede estar asociado con eventos adversos graves en esta población, especialmente en presencia de medicamentos concomitantes y / o comorbilidades

La pregunta es más difícil en pacientes con calidad de vida severamente reducida o en pacientes con demencia terminal. Las consideraciones aquí son duales: menor beneficio y mayor costo. Estos   pacientes obtienen menos beneficios del tratamiento con antibióticos en relación a la disminución de la capacidad funcional, la función cognitiva y la calidad de vida.  Debido a la exposición frecuente al sistema de salud, tienen más probabilidades de estar colonizados con bacterias resistentes a múltiples antibióticos lo que requiere un tratamiento antibiótico empírico de amplio espectro con mayores costos ecológicos.

Dr. José Mauricio Ocampo Chaparro MD, MSc

Work University of Valle

Department of family medicine

Faculty of Medicine

University of Valle, Cali, Colombia

E mail: jose.m.ocampo@correounivalle.edu.co

 

La polifarmacia es definida como el consumo de más de cinco medicamentos de forma simultánea y está relacionada con la alta prevalencia de enfermedades crónicas en la población geriátrica. Es el factor principal para el desarrollo de reacciones adversas a medicamentos, ya que aumenta la probabilidad de efectos colaterales, sobredosis y de interacciones medicamentosas, además de aumentar la posibilidad de no-adherencia, complicar el seguimiento de la terapia e incrementar los costos de atención en salud.

Dentro de sus características se figuran: uso de medicamentos contraindicados y no indicados, duplicación de medicamentos, dosis inapropiada y uso de medicamentos para el manejo de reacciones medicamentosas. Esta última constituye lo que se conoce como la cascada de la prescripción.

El médico tiene un papel importante para evitar que se presente polifarmacia y abuso de medicamentos en el anciano. Dentro de sus acciones a tener en cuenta están:

  • Iniciar con manejo no farmacológico.
  • Realizar durante cada consulta adecuada historia farmacológica que incluya: presentación, dosis y frecuencia de administración de medicamentos que consume el anciano, para así evitar prescripciones repetidas.
  • Conocer la farmacología de los medicamentos prescritos.
  • Empezar la terapia farmacológica con el menor número de medicamentos, a bajas dosis y aumentar de forma progresiva.
  • Evitar manejos sintomáticos.
  • Evitar la prescripción de medicamentos de reciente salida al mercado, ya que la mayoría de los estudios clínicos son realizados en personas jóvenes.
  • Brindar educación al paciente y su familia que permita obtener mayor adherencia al tratamiento, disminuir los errores de medicación y optimizar la acción farmacológica.

Por otra parte, en el anciano son habituales presentaciones atípicas de RAM, principalmente en forma de síndromes geriátricos: delírium, deterioro cognoscitivo, depresión, inestabilidad y caídas, retención urinaria e incontinencia de esfínteres, estreñimiento o diarrea y parkinsonismo. También es frecuente la declinación funcional.

 

 

Abstract / Conference (250 a 300 words)

POLYPHARMACY AND GERIATRIC SYNDROMES

Dr. José Mauricio Ocampo Chaparro MD, MSc

Department of Family Medicine, Faculty of Medicine, University of Valle, Cali, Colombia

E mail: jose.m.ocampo@correounivalle.edu.co

 

Polypharmacy is defined as the consumption of more than five medications simultaneously and is related to the high prevalence of chronic diseases in the geriatric population. It is the main factor for the development of adverse drug reactions, since it increases the likelihood of side effects, overdose and drug interactions, as well as increasing the possibility of non-adherence, complicating therapy monitoring and increasing care costs in health.

Its characteristics include: use of contraindicated and non-indicated medications, duplication of medications, inappropriate dosage and use of medications for the management of drug reactions. The latter constitutes what is known as the prescription cascade.

The doctor has an important role to prevent polypharmacy and drug abuse in the elderly. Among its actions to consider are:

  • Start with non-pharmacological management.
  • Perform during each appropriate consultation pharmacological history that includes: presentation, dose and frequency of administration of medications consumed by the elderly, to avoid repeated prescriptions.
  • Know the pharmacology of prescribed medications.
  • Start drug therapy with the least number of medications, at low doses and increase progressively.
  • Avoid symptomatic management.
  • Avoid prescribing medications recently released, since most clinical studies are conducted in young people.
  • Provide education to the patient and his family that allows to obtain greater adherence to treatment, reduce medication errors and optimize pharmacological action.

On the other hand, atypical presentations of ADR are common in the elderly, mainly in the form of geriatric syndromes: delirium, cognitive impairment, depression, instability and falls, urinary retention and sphincter incontinence, constipation or diarrhea and parkinsonism. Functional decline is also frequent.

Ps. Jéssica López Peláez. MSc

Work: University of Santiago de Cali, Cali, Colombia

Ex: Psychology Department

Faculty of  Health

E mail:jessica.lopez02@usc.edu.co

CURRICULAR SUMMARY (maximun ten lines)

Ex.  Psychologist from the Universidad de los Andes. She has a Masters in Cognitive Psychology, with postgraduate studies in psychocardiology and psycho-oncology at the University of Buenos Aires. She is a clinical resident in Surgical Psychoprophylaxis at the Durand Hospital of Buenos Aires. She is also a research professor at the Faculty of Health at the Santiago de Cali, and a member of the Association of Palliative Care of Colombia and the Latin American Association of Palliative Care.

She has clinical, teaching and research experience is in the field of Health Psychology and Palliative Care.

 

NAME YOUR CONFERENCE: INGLES AND SPANISH

Post Surgical Pain Management In Patients With Renal Transplantation With Pharmacological Vs Non-Pharmacological Intervention

Manejo Del Dolor Post Quirúrgico En Pacientes Con Trasplante Renal Con Intervención Farmacológica Vs No Farmacológica

…………………………………………………………………………………………………………

ANEXAR ABSTRACT DE SU PRESENTACION. MAXIMO 300 palbras.

Abstract / Conference (250 a 300 words) ………………..

Introduction

Chronic Renal Disease (CKD) is one of the most prevalent pathologies worldwide. As the disease progresses, there is a degeneration of the kidney causing in some cases a kidney transplant. Waiting for a transplant alters the patient psychologically and emotionally, finding high levels of anxiety and fear for the pain of the intervention.

The objective of this research is to make a comparison of pharmacological vs. non-pharmacological intervention in the management of postoperative pain in kidney transplant recipients.

Materials and methods: A systematic search was conducted in the main databases ScientDirect, EBSCO, Gale, PubMed, using as keywords: renal transplant, pain, pharmacological, post-surgical, intervention, treatment and alternative therapies, in a time window from 2001 to 2016. We selected 20 articles, of these 9 focus on the most commonly used analgesic drugs (opioids and NSAIDs), 9 focus on the different alternative techniques most used in pain management, 2 are based on other techniques that are rarely used but are effective against pain management, as well as other drugs that help reduce this symptom.

The results obtained demonstrated scientific evidence with pharmacological management, as a first choice the use of opioid drugs and NSAIDs as coadjuvants or second choice, in addition has been shown to have a better analgesic effect of continuous use in pre, intra and postoperative procedures using the union of different groups of drugs such as NSAIDs, COX-2 inhibitors, and drugs for neuropathic pain, without ignoring that the combination of both pharmacological and non-pharmacological interventions are more effective for the recovery of the kidney transplant patient.

Conclusions: although the first choice management for postoperative pain in kidney transplant patients is pharmacological intervention, it would be useful to include alternative therapies such as mindfulness, acupuncture and meditation in the treatment.

It is considered convenient to implement a comprehensive pain management program, because pain control reduces hospitalization recurrence, contributing to quality of life and reducing costs in the health system.

Daniel Romero Urrea

Médico Cirujano – Universidad del Valle

Ciencias Biomédicas (Enfasis en Farmacología y Neurociencias) – Universidad del Valle

Enfasis en Farmacología y Neurociencias

 

Conferencia

Efectos del microbioma humano sobre la administración de medicamentos: ¿Es necesaria otra rama de la farmacología?

Abstract

En un cuerpo humano adulto se pueden encontrar típicamente diez veces más células microbianas que la totalidad de las células que lo comprenden. Este ecosistema microbiano ha evolucionado juntamente con el Homo sapiens y sirve para numerosas funciones vitales para su huésped humano, incluida la protección contra patógenos, el procesamiento de nutrientes y puede el comportamiento de numerosos fármacos. Hasta el momento en la práctica clínica no se ha tenido en cuenta el efecto del microbioma sobre la terapéutica, ni las implicaciones en el pronóstico de los tratamientos. La ecofisiología intestinal puede tener consecuencias para todos los aspectos farmacológicos de los medicamentos.